Higher-risk populations of DLBCL have been identified, such as the 20–25% of patients with high protein expression of Myc and Bcl2 as well as 5–10% of patients with MYC gene rearrangements5,6. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.